In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) – Global Forecast to 2027
The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.
“The kits & reagents segment accounted for the highest share in the ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.
“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.
“Asia Pacific: The fastest-growing country in the in situ hybridization market”
The in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW. The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
“The kits & reagents segment accounted for the highest share in the ISH consumables market revenue for the year 2021”
The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.
“Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021”
Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.
“Asia Pacific: The fastest-growing country in the in situ hybridization market”
The in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW. The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the Asia Pacific.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80% and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
- Abbott (US)
- Abcam (UK)
- Abnova Corporation (Taiwan)
- Agilent Technologies, Inc. (US)
- Bio SB Inc. (US)
- Biocare Medical, LLC (US)
- BioCat GmbH (Germany)
- BioGenex Laboratories (US)
- Bio-Rad Laboratories (US)
- Bio-Techne Corporation (US)
- BioView (Israel)
- Creative Bioarray (US)
- Danaher (US)
- Enzo Biochem (US)
- F. Hoffmann-La Roche AG (Switzerland)
- GeneMed Biotechnologies Inc. (US)
- Merck KGaA (Germany)
- NeoGenomics Laboratories (US)
- OpGen (US)
- Oxford Gene Technology (UK)
- PerkinElmer Inc. (US)
- QIAGEN N.V. (Netherlands)
- Thermo Fisher Scientific (US)
- ZytoVision GmbH (Germany)
This report provides a detailed picture of the in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION)
FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022?2027)
FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION & TRIANGULATION
2.3.1 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 10 FLUORESCENT IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
FIGURE 11 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 IN SITU HYBRIDIZATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF IN SITU HYBRIDIZATION MARKET
4 PREMIUM INSIGHTS
4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW
FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET
4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET
FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021
4.3 IN SITU HYBRIDIZATION MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of genetic disorders and cancer
5.2.1.2 Growing awareness of companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Emerging economies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF BUYERS
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 18 IN SITU HYBRIDIZATION MARKET: SUPPLY CHAIN
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET
5.6 ECOSYSTEM ANALYSIS
FIGURE 20 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS
5.7 KEY CONFERENCES & EVENTS (2020?2022)
5.7.1 IN SITU HYBRIDIZATION CONFERENCES (2022)
TABLE 3 IN SITU HYBRIDIZATION CONFERENCES (2022)
5.7.2 IN SITU HYBRIDIZATION CONFERENCES (2021)
5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020)
TABLE 4 IN SITU HYBRIDIZATION CONFERENCES (2020)
5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION)
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS
5.9.1 IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 10 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 11 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 12 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PROBES
6.2.1.1 Preference for direct localization of DNA/RNA sequences using probes
TABLE 16 IN SITU HYBRIDIZATION MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Growing focus on companion diagnostics to drive demand
TABLE 20 IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 ACCESSORIES
TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH
TABLE 28 IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SOFTWARE
6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
TABLE 32 IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 36 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 FLUORESCENT IN SITU HYBRIDIZATION
TABLE 37 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 DNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.1 Rising need to ensure stability of genetic material to drive market
TABLE 42 DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.2.1 Increasing biomedical research activity to support market growth
TABLE 46 RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 PNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market
TABLE 50 PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CHROMOGENIC IN SITU HYBRIDIZATION
7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH
TABLE 54 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 58 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 CANCER DIAGNOSTICS
8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET
TABLE 59 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CYTOLOGY
8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH
TABLE 63 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 INFECTIOUS DISEASE DIAGNOSTICS
8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET
TABLE 67 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 NEUROSCIENCE
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH
TABLE 71 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 IMMUNOLOGY
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET
TABLE 75 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9 IN SITU HYBRIDIZATION MARKET, BY END USER
9.1 INTRODUCTION
TABLE 79 IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS
TABLE 80 IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH
TABLE 84 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET
TABLE 88 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 92 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 IN SITU HYBRIDIZATION MARKET, BY REGION
10.1 INTRODUCTION
TABLE 96 IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 97 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027(USD MILLION)
TABLE 103 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Rising government funding for life science research to drive market
TABLE 104 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 105 US: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 107 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing investments in genomics research to drive market
TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 111 CANADA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 113 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 116 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 118 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Rising demand for technologically advanced diagnostic procedures to drive market
TABLE 123 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 GERMANY: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 126 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 127 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Growing investments in proteomics and genomics to drive market
TABLE 129 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 FRANCE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 132 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 133 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing focus on cancer research to drive market for ISH
TABLE 135 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 136 UK: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 138 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.4 REST OF EUROPE (ROE)
TABLE 141 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 142 REST OF EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 144 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 145 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 147 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 152 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising focus on personalized diagnostics products to support market growth
TABLE 154 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 JAPAN: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 157 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising annual R&D investments to drive market demand for FISH and CISH-based kits
TABLE 160 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161 CHINA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 163 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 164 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 165 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market
TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 167 INDIA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 171 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 172 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 178 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 179 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 REST OF THE WORLD: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 181 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 182 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 183 REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS
FIGURE 23 IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 24 IN SITU HYBRIDIZATION MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021)
11.4 REVENUE SHARE ANALYSIS
FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019?2021)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 26 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 27 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021)
11.6.5 COMPETITIVE BENCHMARKING
11.6.5.1 In situ hybridization market: Startups/SMEs
TABLE 185 LIST OIN SITU HYBRIDIZATION MARKET: STARTUPS/SMES
11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs)
TABLE 186 IN SITU HYBRIDIZATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
11.7 COMPETITIVE SCENARIO AND TRENDS
11.7.1 DEALS
TABLE 187 IN SITU HYBRIDIZATION MARKET: DEALS
11.7.2 PRODUCT LAUNCHES
TABLE 188 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT
TABLE 189 ABBOTT: BUSINESS OVERVIEW
FIGURE 28 ABBOTT: COMPANY SNAPSHOT
TABLE 190 ABBOTT: PRODUCTS OFFERED
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 192 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 193 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
12.1.4 DANAHER
TABLE 196 DANAHER: BUSINESS OVERVIEW
FIGURE 31 DANAHER: COMPANY SNAPSHOT
TABLE 197 DANAHER: PRODUCTS OFFERED
TABLE 198 PRODUCT APPROVALS
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW
TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED
12.1.6 BIOCARE MEDICAL, LLC
TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
TABLE 202 BIOCARE MEDICAL, LLC: PRODUCTS OFFERED
12.1.7 BIO-TECHNE CORPORATION
TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES
12.1.8 QIAGEN N.V.
TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW
TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED
12.1.9 MERCK KGAA
TABLE 207 MERCK KGAA: BUSINESS OVERVIEW
TABLE 208 MERCK KGAA: PRODUCTS OFFERED
12.1.10 PERKINELMER
TABLE 209 PERKINELMER: BUSINESS OVERVIEW
TABLE 210 PERKINELMER: PRODUCTS OFFERED
12.1.11 ENZO BIOCHEM
TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW
FIGURE 37 ENZO BIOCHEM: COMPANY SNAPSHOT
TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED
12.1.12 BIO-RAD LABORATORIES
TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED
12.1.13 ABNOVA CORPORATION
TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.14 BIOGENEX LABORATORIES
TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED
12.1.15 OPGEN
TABLE 219 OPGEN: BUSINESS OVERVIEW
TABLE 220 OPGEN INC: PRODUCTS OFFERED
12.1.16 BIO SB
TABLE 221 BIO SB: BUSINESS OVERVIEW
TABLE 222 BIO SB: PRODUCTS OFFERED
12.1.17 ABCAM
TABLE 223 ABCAM: BUSINESS OVERVIEW
TABLE 224 ABCAM: PRODUCTS OFFERED
12.1.18 ZYTOMED SYSTEMS GMBH
TABLE 225 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
TABLE 226 ZYTOMED SYSTEMS: PRODUCTS OFFERED
12.1.19 NEOGENOMICS LABORATORIES
TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
12.1.20 BIOVIEW
TABLE 229 BIOVIEW: BUSINESS OVERVIEW
TABLE 230 BIOVIEW: PRODUCTS OFFERED
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 GENEMED BIOTECHNOLOGIES
TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW
12.2.2 CREATIVE BIOARRAY
TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW
12.2.3 BIOCAT GMBH
TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW
12.2.4 OXFORD GENE TECHNOLOGY
TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW
12.2.5 ZYTOVISION
TABLE 235 ZYTOVISION: BUSINESS OVERVIEW
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION)
FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022?2027)
FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION & TRIANGULATION
2.3.1 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY
FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 10 FLUORESCENT IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
FIGURE 11 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 IN SITU HYBRIDIZATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF IN SITU HYBRIDIZATION MARKET
4 PREMIUM INSIGHTS
4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW
FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET
4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET
FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021
4.3 IN SITU HYBRIDIZATION MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of genetic disorders and cancer
5.2.1.2 Growing awareness of companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Emerging economies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF BUYERS
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 18 IN SITU HYBRIDIZATION MARKET: SUPPLY CHAIN
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET
5.6 ECOSYSTEM ANALYSIS
FIGURE 20 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS
5.7 KEY CONFERENCES & EVENTS (2020?2022)
5.7.1 IN SITU HYBRIDIZATION CONFERENCES (2022)
TABLE 3 IN SITU HYBRIDIZATION CONFERENCES (2022)
5.7.2 IN SITU HYBRIDIZATION CONFERENCES (2021)
5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020)
TABLE 4 IN SITU HYBRIDIZATION CONFERENCES (2020)
5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION)
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS
5.9.1 IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 10 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 11 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 12 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PROBES
6.2.1.1 Preference for direct localization of DNA/RNA sequences using probes
TABLE 16 IN SITU HYBRIDIZATION MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Growing focus on companion diagnostics to drive demand
TABLE 20 IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 ACCESSORIES
TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH
TABLE 28 IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SOFTWARE
6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
TABLE 32 IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 36 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 FLUORESCENT IN SITU HYBRIDIZATION
TABLE 37 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 DNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.1 Rising need to ensure stability of genetic material to drive market
TABLE 42 DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.2.1 Increasing biomedical research activity to support market growth
TABLE 46 RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 PNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market
TABLE 50 PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CHROMOGENIC IN SITU HYBRIDIZATION
7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH
TABLE 54 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 58 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 CANCER DIAGNOSTICS
8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET
TABLE 59 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CYTOLOGY
8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH
TABLE 63 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 INFECTIOUS DISEASE DIAGNOSTICS
8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET
TABLE 67 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 NEUROSCIENCE
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH
TABLE 71 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 IMMUNOLOGY
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET
TABLE 75 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9 IN SITU HYBRIDIZATION MARKET, BY END USER
9.1 INTRODUCTION
TABLE 79 IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS
TABLE 80 IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH
TABLE 84 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET
TABLE 88 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 92 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 IN SITU HYBRIDIZATION MARKET, BY REGION
10.1 INTRODUCTION
TABLE 96 IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 97 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027(USD MILLION)
TABLE 103 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Rising government funding for life science research to drive market
TABLE 104 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 105 US: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 107 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing investments in genomics research to drive market
TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 111 CANADA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 113 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 116 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 118 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Rising demand for technologically advanced diagnostic procedures to drive market
TABLE 123 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 GERMANY: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 126 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 127 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Growing investments in proteomics and genomics to drive market
TABLE 129 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 FRANCE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 132 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 133 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing focus on cancer research to drive market for ISH
TABLE 135 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 136 UK: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 138 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.4 REST OF EUROPE (ROE)
TABLE 141 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 142 REST OF EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 144 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 145 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 147 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 152 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising focus on personalized diagnostics products to support market growth
TABLE 154 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 JAPAN: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 157 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising annual R&D investments to drive market demand for FISH and CISH-based kits
TABLE 160 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161 CHINA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 163 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 164 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 165 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market
TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 167 INDIA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 171 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 172 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 178 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 179 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 REST OF THE WORLD: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 181 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 182 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 183 REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS
FIGURE 23 IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 24 IN SITU HYBRIDIZATION MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021)
11.4 REVENUE SHARE ANALYSIS
FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019?2021)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 26 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 27 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021)
11.6.5 COMPETITIVE BENCHMARKING
11.6.5.1 In situ hybridization market: Startups/SMEs
TABLE 185 LIST OIN SITU HYBRIDIZATION MARKET: STARTUPS/SMES
11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs)
TABLE 186 IN SITU HYBRIDIZATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
11.7 COMPETITIVE SCENARIO AND TRENDS
11.7.1 DEALS
TABLE 187 IN SITU HYBRIDIZATION MARKET: DEALS
11.7.2 PRODUCT LAUNCHES
TABLE 188 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES
12 COMPANY PROFILES
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT
TABLE 189 ABBOTT: BUSINESS OVERVIEW
FIGURE 28 ABBOTT: COMPANY SNAPSHOT
TABLE 190 ABBOTT: PRODUCTS OFFERED
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 192 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 193 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
12.1.4 DANAHER
TABLE 196 DANAHER: BUSINESS OVERVIEW
FIGURE 31 DANAHER: COMPANY SNAPSHOT
TABLE 197 DANAHER: PRODUCTS OFFERED
TABLE 198 PRODUCT APPROVALS
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW
TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED
12.1.6 BIOCARE MEDICAL, LLC
TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
TABLE 202 BIOCARE MEDICAL, LLC: PRODUCTS OFFERED
12.1.7 BIO-TECHNE CORPORATION
TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES
12.1.8 QIAGEN N.V.
TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW
TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED
12.1.9 MERCK KGAA
TABLE 207 MERCK KGAA: BUSINESS OVERVIEW
TABLE 208 MERCK KGAA: PRODUCTS OFFERED
12.1.10 PERKINELMER
TABLE 209 PERKINELMER: BUSINESS OVERVIEW
TABLE 210 PERKINELMER: PRODUCTS OFFERED
12.1.11 ENZO BIOCHEM
TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW
FIGURE 37 ENZO BIOCHEM: COMPANY SNAPSHOT
TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED
12.1.12 BIO-RAD LABORATORIES
TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED
12.1.13 ABNOVA CORPORATION
TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.14 BIOGENEX LABORATORIES
TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED
12.1.15 OPGEN
TABLE 219 OPGEN: BUSINESS OVERVIEW
TABLE 220 OPGEN INC: PRODUCTS OFFERED
12.1.16 BIO SB
TABLE 221 BIO SB: BUSINESS OVERVIEW
TABLE 222 BIO SB: PRODUCTS OFFERED
12.1.17 ABCAM
TABLE 223 ABCAM: BUSINESS OVERVIEW
TABLE 224 ABCAM: PRODUCTS OFFERED
12.1.18 ZYTOMED SYSTEMS GMBH
TABLE 225 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
TABLE 226 ZYTOMED SYSTEMS: PRODUCTS OFFERED
12.1.19 NEOGENOMICS LABORATORIES
TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
12.1.20 BIOVIEW
TABLE 229 BIOVIEW: BUSINESS OVERVIEW
TABLE 230 BIOVIEW: PRODUCTS OFFERED
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 GENEMED BIOTECHNOLOGIES
TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW
12.2.2 CREATIVE BIOARRAY
TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW
12.2.3 BIOCAT GMBH
TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW
12.2.4 OXFORD GENE TECHNOLOGY
TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW
12.2.5 ZYTOVISION
TABLE 235 ZYTOVISION: BUSINESS OVERVIEW
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
